References
- Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227–230.
- Charalabidis A, Sfouni M, Bergström C, et al. The biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS): beyond guidelines. Int J Pharm. 2019;566:264–281.
- Félix-Sonda BC, Rivera-Islas J, Herrera-Ruiz D, et al. Nitazoxanide cocrystals in combination with succinic, glutaric, and 2,5-dihydroxybenzoic acid. Cryst Growth Des. 2014;14(3):1086–1102.
- Kohli K, Chopra S, Dhar D, et al. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15(21-22):958–965.
- Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598–613.
- Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603–616.
- Cheirsilp B, Rakmai J. Inclusion complex formation of cyclodextrin with its guest and their applications. Biol Eng Med. 2017;2(1):1–6.
- Joshi JT. A review on micronization techniques. J Pharm Sci Technol. 2011;3(7):651–681.
- Baghel S, Cathcart H, O’Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105(9):2527–2544.
- Punitha S, Srinivasa Reddy G, Srikrishna T, et al. Solid dispersions: a review. Res J Pharm Technol. 2011;4(3):331–334.
- Jambhekar SS, Breen PJ. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov Today. 2013;18(23-24):1173–1184.
- Aldawsari HM, Singh S. Rapid microwave-assisted cisplatin-loaded solid lipid nanoparticles: synthesis, characterization and anticancer study. Nanomaterials. 2020;10(3):510.
- Ali NW, Abbas SS, Zaazaa HES, et al. Validated stability indicating methods for determination of nitazoxanide in presence of its degradation products. J Pharm Anal. 2012;2(2):105–116.